<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841824</url>
  </required_header>
  <id_info>
    <org_study_id>APHP201060</org_study_id>
    <nct_id>NCT04841824</nct_id>
  </id_info>
  <brief_title>TRanscriptomic Analysis of Circulating Endothelial Cells During Sepsis - TRACES Study</brief_title>
  <acronym>TRACES</acronym>
  <official_title>Dysfunction and Endothelial Repair in Sepsis Shock : RNAseq Transcriptomic Analysis of Circulating Endothelial Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular dysfunction is an important mechanism involved in organ failure, in the setting of&#xD;
      sepsis condition, with different types of circulating endothelial cells.Transcriptom analysis&#xD;
      via RNAseq in different types of circulating endothelial cells, comapring critically ill&#xD;
      patients with or without sepsis will allow determining differential gene expression for&#xD;
      signal pathways in endothelial alteration and restoration associated with sepsis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">August 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression based on transcriptom analysis of circulating endothelial cells</measure>
    <time_frame>Day 1</time_frame>
    <description>Gene expression based on transcriptom analysis of circulating endothelial cells (RNAseq)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Counts of circulating endothelial cells</measure>
    <time_frame>Day 1 and Day 3</time_frame>
    <description>Counts of circulating endothelial cells, including progenitor cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) score</measure>
    <time_frame>Day 1, Day 3, Day 7</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) score, ranging from 0 (best: absence of organ failure) to 24 (worse: multiple organ failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) hemodynamic sub-score</measure>
    <time_frame>Day 1, Day 3, Day 7</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) hemodynamic sub-score, ranging from 0 (best: absence of hemodynamic failure) to 4 (worse: hemodynamic failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) respiratory sub-score</measure>
    <time_frame>Day 1, Day 3, Day 7</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) respiratory sub-score, ranging from 0 (best: absence of respiratory failure) to 4 (worse: respiratory failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) neurological sub-score</measure>
    <time_frame>Day 1, Day 3, Day 7</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) neurological sub-score, ranging from 0 (best: absence of neurological failure) to 4 (worse: neurological failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) hematological sub-score</measure>
    <time_frame>Day 1, Day 3, Day 7</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) hematological sub-score, ranging from 0 (best: absence of hematological failure) to 4 (worse: hematological failure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit (ICU) mortality</measure>
    <time_frame>ICU length of stay</time_frame>
    <description>Death during ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D28 mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Death within 28 days of intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>Death within 90 days of intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days alive without ventilation up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of renal replacement therapy (RRT)</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days alive without RRT up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasopressors therapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days alive without vasopressors up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of vasopressors</measure>
    <time_frame>ICU length of stay, assessed up to 90 days</time_frame>
    <description>Dose of vasopressors, in patients who received vasopressors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intensive care unit (ICU) stay</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of days alive outside the ICU up to D28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating endothelial cells cytokines profile</measure>
    <time_frame>Day 1 and 3</time_frame>
    <description>Dosage of cytokines from circulating endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating endothelial cells chemokines profile</measure>
    <time_frame>Day 1 and 3</time_frame>
    <description>Dosage of chemokines from circulating endothelial cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression of membrane proteins of endothelial cells</measure>
    <time_frame>Day 1 and 3</time_frame>
    <description>Expression of membrane proteins of endothelial cells by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection site</measure>
    <time_frame>Day 1</time_frame>
    <description>Infection site for patients with sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection identification</measure>
    <time_frame>Day 1</time_frame>
    <description>Identified germs for patients with sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with different types of antibiotic treatment</measure>
    <time_frame>Length of ICU stay, assessed up to 90 days</time_frame>
    <description>Antibiotic treatments for patients with sepsis during intensive care unit (ICU) stay</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Critical Illness With or Without Sepsis</condition>
  <arm_group>
    <arm_group_label>Critically ill patients with sepsis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Critically ill patients without sepsis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Observational study. Groups are defined based on baseline patients' characteristics : presence or absence of sepsis.</description>
    <arm_group_label>Critically ill patients with sepsis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill adult patients hospitalized in an intensive care unit, with or without&#xD;
        sepsis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 85 years&#xD;
&#xD;
          -  Admission in intensive care with or without sepsis&#xD;
&#xD;
          -  Health insurance as per the national insurance system&#xD;
&#xD;
          -  Informed and unopposed patient for participation (or referend closed one)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under legal protection&#xD;
&#xD;
          -  Patient under national medical help system&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lara Zafrani, MD PhD</last_name>
    <phone>+33 1 42 49 94 19</phone>
    <email>lara.zafrani@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>AP-HP Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lara Zafrani, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

